Kathryn C Arbour

18PUBLICATIONS
199CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersReinforcement learning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 16, 2026
RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.

Alexander J Pfeil, Tom Zhang, Ryan Cheng

|Jan 09, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.

Jordi Rodon, Melissa L Johnson, Ben George

|Apr 09, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato

|Dec 05, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

Jayesh Desai, Guzman Alonso, Se Hyun Kim

|Aug 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.

Arielle Elkrief, Biagio Riccuiti, Joao V Alessi

|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom, Ruth Aranda, Laura Waters

Pageof 3

Frequent Collaborators

4 joint publications

Andrew Plodkowski

4 joint publications

Bob T Li

4 joint publications

Matthew Hellmann

4 joint publications

Charles M Rudin